TIOTROPIUM BROMIDE
Drug
Chiesi USA, Inc.
Total Payments
$2.2M
Transactions
752
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $2.2M | 752 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 752 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CCD-05993AA3-02 | Chiesi USA, Inc. | $2.2M | 0 |
Top Doctors Receiving Payments for TIOTROPIUM BROMIDE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Fair Oaks, CA | $2.2M | 752 |
Ad
Manufacturing Companies
- Chiesi USA, Inc. $2.2M
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 0
- Transactions 752
About TIOTROPIUM BROMIDE
TIOTROPIUM BROMIDE is a drug associated with $2.2M in payments to 0 healthcare providers, recorded across 752 transactions in the CMS Open Payments database. The primary manufacturer is Chiesi USA, Inc..
Payment data is available from 2017 to 2017. In 2017, $2.2M was paid across 752 transactions to 0 doctors.
The most common payment nature for TIOTROPIUM BROMIDE is "Unspecified" ($2.2M, 100.0% of total).
TIOTROPIUM BROMIDE is associated with 1 research study, including "CCD-05993AA3-02" ($2.2M).